Studies have primarily observed a modest decline in effectiveness among older people and the immunocompromised, which is why some jurisdictions have recommended boosters for these people (Israel, California). There is a reason boosters have not been approved anywhere for the general population, and that is because so far the data does not indicate they are necessary.